MarkHerz Forms TUM Hospital Spin-Off and Launches Korea-Germany Alliance

MarkHerz Inc. has announced the creation of an official spin-off from the Technical University of Munich Hospital, alongside the launch of the Korea-Germany BIO-AI Alliance. This strategic move aims to enhance the global commercialization of AAV-based gene therapies. The initiative combines South Korea's AI-driven manufacturing technologies with German biomedical expertise.

The German spin-off, expected to launch in the first half of 2026, will operate independently but remain affiliated with TUM Klinikum. Dr. Seungmin Lee and Professor Christian Kupatt have formalized this partnership, which builds on 15 years of joint research. This collaboration has led to publications in journals like Nature Medicine and Advanced Science.

Additionally, the company plans to establish an AI-based automated production framework in South Korea and a Korean-style AI Automated GMP Center in Germany. This effort underscores MarkHerz's commitment to integrating clinical and manufacturing expertise to enhance global competitiveness in gene therapy.